Seer (SEER) Competitors

Seer (NASDAQ:SEER) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.

Is SEER or LAB more profitable?

Standard BioTools has a net margin of -79.92% compared to Seer's net margin of -565.83%. Seer's return on equity of -21.96% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-565.83%	-21.96%	-19.85%
Standard BioTools	-79.92%	-27.05%	-15.52%

Do analysts recommend SEER or LAB?

Seer currently has a consensus price target of $3.00, indicating a potential upside of 52.28%. Standard BioTools has a consensus price target of $2.50, indicating a potential upside of 115.52%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Seer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community favor SEER or LAB?

Standard BioTools received 2 more outperform votes than Seer when rated by MarketBeat users. Likewise, 83.33% of users gave Standard BioTools an outperform vote while only 13.64% of users gave Seer an outperform vote.

Company	Underperform	Outperform
Seer	Outperform Votes 3 13.64%	Underperform Votes 19 86.36%
Standard BioTools	Outperform Votes 5 83.33%	Underperform Votes 1 16.67%

Do insiders and institutionals hold more shares of SEER or LAB?

75.2% of Seer shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 15.0% of Seer shares are held by company insiders. Comparatively, 53.1% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has preferable valuation and earnings, SEER or LAB?

Standard BioTools has higher revenue and earnings than Seer. Standard BioTools is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$13.95M	8.44	-$86.28M	-$1.39	-1.42
Standard BioTools	$174.43M	2.52	-$74.66M	-$0.55	-2.11

Does the media prefer SEER or LAB?

In the previous week, Seer and Seer both had 5 articles in the media. Standard BioTools' average media sentiment score of 0.93 beat Seer's score of -0.11 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, SEER or LAB?

Seer has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.

Summary

Standard BioTools beats Seer on 12 of the 17 factors compared between the two stocks.